Immune　checkpoint　blockade　(ICB)　therapy　combined　with　Photodynamic　therapy　(PDT)　has　shown　great　potential　in　the　treatment　of　advanced　metastatic　tumors.　However,　it　is　still　an　important　challenge　to　find　a　simple　and　effective　photosensitizer　for　matching　photodynamic　immunotherapy.　In　this　paper,　we　report　a　treatment　method　that　combines　PDT　caused　by　three　zinc(II)　phthalocyanines　(ZnPcs)　with　a　different　charge,　and　a　checkpoint　inhibition　agent,　namely　anti-PD-L1　antibody,　to　induce　systemic　antitumor　immunity.　Among　the　ZnPcs,　the　neutral　ZnPc　1　showed　the　highest　photodynamic　activity,　while　the　cationic　compound　2　exhibited　the　highest　synergistic　antitumor　effect　with　ICB.　For　ZnPc　2,　the　tumor　inhibition　rate　of　PDT-ICB　combined　therapy　for　distant　tumors　was　found　to　be　as　high　as　89%,　but　PDT　alone　or　ICB　alone　could　hardly　cause　an　inhibitory　effect　in　a　B16–F10　tumor　model.　We　also　detected　an　increase　in　T　cell　infiltration　in　the　tumor　microenvironment　after　the　immune　system　was　activated　by　a　combination　of　anti-PD-L1　antibody　and　PDT.　It　was　interesting　to　find　that　CD8+　T　cells　increased　most　significantly　for　the　combination　of　anti-PD-L1　antibody　and　PDT　by　the　positively　charged　compound　2.　Moreover,　the　combination　of　ZnPc　2-PDT　and　ICB　could　efficiently　inhibit　the　recurrence　of　tumors.　The　results　suggest　that　the　mono-cationic　ZnPc　2　with　a　well-defined　structure　and　ease　of　preparation,　is　a　highly　promising　photosensitizer　specifically　for　PDT　combined　with　immunotherapy.　©　2020　Elsevier　Ltd